Labcorp

LHNYSE

Other · Services-Medical Laboratories · SEC filings ↗ · Compare ⊕

Financials

SEC XBRL · annual

	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$13.95B	$13.01B	$12.16B	$11.86B	$13.14B	$13.98B
Operating income	$1.38B	$1.09B	$725.6M	$1.44B	$3.05B	$2.45B
Net income	$876.5M	$746.0M	$418.0M	$1.28B	$2.38B	$1.56B
Total assets	$18.39B	$18.38B	$16.73B	$20.16B	$20.39B	$20.07B
Total liabilities	$9.76B	$10.31B	$8.83B	$10.04B	$10.09B	$10.61B
Equity	$8.62B	$8.05B	$7.88B	$10.10B	$10.27B	$9.44B
EPS (diluted)	$10.46	$8.84	$4.77	$13.97	$24.39	$15.88
Shares out.	83.7M	84.1M	88.5M	93.4M	97.6M	97.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025

Operating margin: 9.9%
Net margin: 6.3%
Return on equity: 10.2%
Return on assets: 4.8%
Return on capital (ROCE): 8.9%
Liabilities / assets: 53.0%
Debt / equity: 1.13×
Book value / share: $102.98
Revenue growth (YoY): 7.2%
Net income growth (YoY): 17.5%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025

Altman Z″ (distress): 3.39safe
Accruals / assets: −4.2%clean
Beneish M-Score: -2.56normal
Piotroski F-Score: 8/9strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score

/ 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 5 good

Operating margin is positive
Revenue is growing year-over-year
Positive operating cash flow
Clean earnings (low accruals)
Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Vanguard Capital Management LlcPassive (13G)Apr 28, 2026
Vanguard Group IncPassive (13G)Mar 26, 2026
Blackrock, Inc.Passive (13G)Apr 24, 2025

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly

Settlement	Shares short	Days to cover	Δ vs prior
May 15, 2026	3.4M	4.7	+6.8%
Apr 30, 2026	3.2M	4.1	-2.5%
Apr 15, 2026	3.2M	6.0	+1.4%
Mar 31, 2026	3.2M	5.5	+6.7%
Mar 13, 2026	3.0M	5.9	-6.5%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

8-KMay 27, 2026
8-KMay 26, 2026
SDFORM SDMay 22, 2026
4PRIMARY DOCUMENTMay 13, 2026
144May 11, 2026
144May 6, 2026
10-QMay 4, 2026
8-KApr 30, 2026
SCHEDULE 13GApr 28, 2026
ARSApr 10, 2026
DEFA14AApr 10, 2026
DEF 14AApr 10, 2026
8-KApr 9, 2026
8-KMar 31, 2026
4PRIMARY DOCUMENTMar 30, 2026